4. Edwards Lifesciences
R&D spending: $552,600,000
Percentage of revenues: 16.1%
2018 overall revenue ranking: 26Edwards Lifesciences (Irvine, Calif.) continues to tout its Sapien 3 transcatheter aortic valve. The TAVR valves have demonstrated 75% lower rates of 30-day all-cause mortality and disabling stroke compared to surgery in other intermediate-risk patients, according to Edwards.
The Sapien 3 is indicated for relief of aortic stenosis in patients who have symptomatic heart disease from severe native calcific aortic stenosis.